RACE ONCOLOGY
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field.Race Oncology has now rediscovered Bisantrene. In the United States, Race owns two granted patents on Bisantrene and has secured Orphan Drug designation and Rare Paediatric Disease designation. Our goal is to complete clinical development and gain approval by the US FDA.
RACE ONCOLOGY
Industry:
Pharmaceutical
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.raceoncology.com
Status:
Active
Contact:
+61 3 9098 8750
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Nginx Amazon ReCAPTCHA Contact Form 7
Current Employees Featured
Official Site Inspections
http://www.raceoncology.com Semrush global rank: 9.95 M Semrush visits lastest month: 76
Unable to get host informations!!!
More informations about "Race Oncology"
Home - Race Oncology
View share price, top shareholders, your shareholding, and interact with announcements for Race Oncology.See details»
Company Overview - Race Oncology
Race Oncology (ASX: RAC) is an Australian (ASX-listed) clinical stage, biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Our focus is on addressing the high unmet need of cancer patients for …See details»
Board and Management - Race Oncology
Learn more about Race Oncology’s board of directors and the management team. Dr Peter Smith has over 30 years of experience in the pharmaceutical and biotech industry, with a strong focus on therapeutics, especially oncology. He …See details»
Race Oncology investor hub | ASX:RAC
Welcome to Race Oncology's (ASX:RAC) investor hub. View and interact with market data, announcements, annual reports, and investor presentations.See details»
Race Oncology - LinkedIn
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule...See details»
ASX Announcement Race Oncology Board Renewal Update
Learn more at www.raceoncology.com. If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub...See details»
Welcome to the Race Oncology investor hub!
We welcome our shareholders and prospective shareholders to join the ASX:RAC investor hub and engage with the community.See details»
Race Board and Management Team Changes - Race Oncology
Aug 22, 2023 · Questions can be emailed to Mary Harney via [email protected] or submitted via the Race Investor Hub, using this link: https://announcements.raceoncology.com. -ENDS- About Race Oncology (ASX: RAC) Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care.See details»
ASX Announcement - Australian Financial Review
Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule...See details»
Race Oncology investor hub
View share price, top shareholders, your shareholding, and interact with announcements for Race Oncology.See details»
RAC News, Analysis, Announcements & Results | Race Oncology …
Nov 18, 2024 · Cancer biotech Race Oncology is tapping its base of loyal retail shareholders for a fresh capital raise of up to $30 million, Four years ago, Reinsurance Australia Corporation was forced into...See details»
Investor Centre - Race Oncology
Here you will find information on our latest ASX announcements, investor presentations and other shareholder information. Our investors are a valued partner in the business and we are dedicated to fostering an open dialogue and trusting relationship.See details»
Race Receives Cardioprotection Ethics Trial Approval
Race Receives Human Ethics Approval for Observational Cardioprotection Breast Cancer Trial: - Human ethics approval received for the initial observational stage of a plannedinterventional Phase 1/2b cardioprotection clinical program using ZantreneSee details»
Meet The Board - Race Oncology
View share price, top shareholders, your shareholding, and interact with announcements for Race Oncology.See details»
Race Oncology | Melbourne VIC - Facebook
Race Oncology, Melbourne, Victoria, Australia. 244 likes · 1 talking about this. Race Oncology is a specialty pharmaceutical company, whose business...See details»
Race appoints former Sanofi executive to the Board
Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the US, and he has consulted to the World Health Organization and the World Bank.See details»
ASX:RAC - MST Access research report September 2024
MST Access Senior Life Sciences Analyst Chris Kallos published the latest research report on Race Oncology, noting an improved valuation of the company at A$6.37 (prev. A$3.22) based on three key highlights post Race's full year reporting:Bisantrene is the enabler forhigher dosing of anthracyclinesRC220 to enter human clinical trials in 2H...See details»
Race Oncology ASX:RAC Stock Report - Simply Wall St
6 days ago · Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company’s lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients.See details»
Our Science - Race Oncology
Statistical analysis was performed using the non-parametric Wilcoxon matched-pairs signed rank test. View share price, top shareholders, your shareholding, and interact with announcements for Race Oncology.See details»
Race Oncology investor hub | ASX:RAC
Race Oncology investor hub | ASX:RACSee details»